 Godela Brosnahan
Concepts (136)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Polycystic Kidney, Autosomal Dominant | 26 | 2025 | 262 | 4.710 |
Why?
| | Kidney | 17 | 2022 | 1468 | 1.570 |
Why?
| | Glomerular Filtration Rate | 15 | 2022 | 746 | 1.360 |
Why?
| | Kidney Failure, Chronic | 6 | 2020 | 570 | 1.290 |
Why?
| | Disease Progression | 17 | 2025 | 2757 | 1.060 |
Why?
| | Renal Insufficiency, Chronic | 6 | 2025 | 617 | 0.990 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 6 | 2018 | 201 | 0.750 |
Why?
| | Hypertension | 8 | 2018 | 1295 | 0.740 |
Why?
| | Antihypertensive Agents | 5 | 2018 | 494 | 0.670 |
Why?
| | Uric Acid | 1 | 2021 | 163 | 0.640 |
Why?
| | Nephrology | 2 | 2025 | 61 | 0.620 |
Why?
| | Angiotensin Receptor Antagonists | 2 | 2018 | 92 | 0.570 |
Why?
| | Renin-Angiotensin System | 2 | 2018 | 85 | 0.570 |
Why?
| | Metformin | 1 | 2021 | 331 | 0.550 |
Why?
| | Benzoates | 3 | 2014 | 43 | 0.520 |
Why?
| | Blood Pressure | 8 | 2018 | 1786 | 0.480 |
Why?
| | TRPP Cation Channels | 5 | 2020 | 85 | 0.440 |
Why?
| | Specialization | 1 | 2014 | 144 | 0.390 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 445 | 0.380 |
Why?
| | Polymyalgia Rheumatica | 1 | 2008 | 3 | 0.300 |
Why?
| | Iron Chelating Agents | 1 | 2008 | 18 | 0.300 |
Why?
| | Nephritis, Interstitial | 1 | 2008 | 14 | 0.290 |
Why?
| | Middle Aged | 21 | 2021 | 33479 | 0.280 |
Why?
| | Triazoles | 1 | 2008 | 147 | 0.270 |
Why?
| | Adult | 21 | 2021 | 37929 | 0.240 |
Why?
| | Attitude of Health Personnel | 1 | 2014 | 1171 | 0.240 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2014 | 1329 | 0.230 |
Why?
| | Physicians | 1 | 2014 | 910 | 0.230 |
Why?
| | Lisinopril | 2 | 2014 | 13 | 0.230 |
Why?
| | Mutation | 5 | 2020 | 3958 | 0.220 |
Why?
| | Creatinine | 4 | 2018 | 499 | 0.210 |
Why?
| | Benzimidazoles | 2 | 2014 | 170 | 0.210 |
Why?
| | Humans | 32 | 2025 | 137585 | 0.200 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2018 | 1477 | 0.190 |
Why?
| | Male | 23 | 2022 | 67762 | 0.190 |
Why?
| | Female | 24 | 2025 | 73304 | 0.190 |
Why?
| | Young Adult | 9 | 2020 | 13209 | 0.190 |
Why?
| | Kidney Transplantation | 1 | 2008 | 708 | 0.190 |
Why?
| | Prospective Studies | 6 | 2022 | 7604 | 0.180 |
Why?
| | Risk Assessment | 3 | 2020 | 3457 | 0.160 |
Why?
| | Time Factors | 4 | 2018 | 6828 | 0.160 |
Why?
| | Treatment Outcome | 4 | 2018 | 10811 | 0.150 |
Why?
| | Age Factors | 2 | 2018 | 3295 | 0.140 |
Why?
| | Adolescent | 8 | 2018 | 21513 | 0.140 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 2 | 2014 | 38 | 0.140 |
Why?
| | Evidence-Based Medicine | 2 | 2014 | 740 | 0.140 |
Why?
| | Medical History Taking | 1 | 2017 | 117 | 0.140 |
Why?
| | Kidney Function Tests | 1 | 2018 | 160 | 0.140 |
Why?
| | Feasibility Studies | 1 | 2021 | 956 | 0.140 |
Why?
| | Sodium Chloride, Dietary | 1 | 2016 | 36 | 0.130 |
Why?
| | Enalapril | 3 | 2002 | 16 | 0.130 |
Why?
| | Diet, Sodium-Restricted | 1 | 2016 | 36 | 0.130 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2020 | 752 | 0.120 |
Why?
| | Bayes Theorem | 1 | 2018 | 405 | 0.120 |
Why?
| | Multicenter Studies as Topic | 1 | 2017 | 310 | 0.120 |
Why?
| | Risk Factors | 3 | 2017 | 10388 | 0.120 |
Why?
| | Hepatomegaly | 1 | 2014 | 4 | 0.110 |
Why?
| | Artificial Intelligence | 1 | 2018 | 279 | 0.110 |
Why?
| | Longitudinal Studies | 3 | 2018 | 2844 | 0.110 |
Why?
| | Linoleic Acids, Conjugated | 1 | 2013 | 8 | 0.110 |
Why?
| | Endothelium | 1 | 2014 | 123 | 0.110 |
Why?
| | Organ Size | 3 | 2020 | 477 | 0.100 |
Why?
| | Sex Factors | 1 | 2018 | 2071 | 0.090 |
Why?
| | Amlodipine | 2 | 2002 | 9 | 0.090 |
Why?
| | Proteinuria | 2 | 2010 | 97 | 0.090 |
Why?
| | Perception | 1 | 2014 | 359 | 0.090 |
Why?
| | Genotype | 4 | 2020 | 1916 | 0.090 |
Why?
| | Incidence | 1 | 2018 | 2804 | 0.090 |
Why?
| | Hyperphosphatemia | 1 | 2010 | 15 | 0.080 |
Why?
| | Chronic Kidney Disease-Mineral and Bone Disorder | 1 | 2010 | 14 | 0.080 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2828 | 0.080 |
Why?
| | Prognosis | 1 | 2018 | 4030 | 0.080 |
Why?
| | Acidosis | 1 | 2010 | 101 | 0.080 |
Why?
| | Comorbidity | 1 | 2014 | 1622 | 0.070 |
Why?
| | Iron Overload | 1 | 2008 | 17 | 0.070 |
Why?
| | Anemia | 1 | 2010 | 170 | 0.070 |
Why?
| | Oxidative Stress | 1 | 2014 | 1317 | 0.070 |
Why?
| | Arteriovenous Shunt, Surgical | 1 | 2007 | 18 | 0.070 |
Why?
| | Prednisone | 1 | 2008 | 240 | 0.070 |
Why?
| | Drug Hypersensitivity | 1 | 2008 | 90 | 0.070 |
Why?
| | Myelodysplastic Syndromes | 1 | 2008 | 135 | 0.060 |
Why?
| | Erythrocyte Transfusion | 1 | 2008 | 194 | 0.060 |
Why?
| | Eosinophils | 1 | 2008 | 332 | 0.060 |
Why?
| | Practice Guidelines as Topic | 1 | 2014 | 1587 | 0.060 |
Why?
| | Acute Disease | 1 | 2008 | 1007 | 0.060 |
Why?
| | Practice Patterns, Physicians' | 1 | 2014 | 1313 | 0.060 |
Why?
| | Diagnosis, Differential | 1 | 2008 | 1483 | 0.050 |
Why?
| | Obesity | 1 | 2017 | 2992 | 0.050 |
Why?
| | Glucocorticoids | 1 | 2008 | 594 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 3 | 2022 | 3566 | 0.050 |
Why?
| | Renal Dialysis | 1 | 2007 | 435 | 0.050 |
Why?
| | Prevalence | 1 | 2010 | 2734 | 0.050 |
Why?
| | Hypertrophy, Left Ventricular | 2 | 2002 | 131 | 0.050 |
Why?
| | Predictive Value of Tests | 2 | 2020 | 2031 | 0.050 |
Why?
| | Drug Therapy, Combination | 2 | 2014 | 1066 | 0.050 |
Why?
| | Cysts | 1 | 2022 | 113 | 0.040 |
Why?
| | Liver | 2 | 2022 | 1943 | 0.040 |
Why?
| | Double-Blind Method | 2 | 2014 | 1993 | 0.040 |
Why?
| | Body Height | 1 | 2020 | 199 | 0.040 |
Why?
| | Calcium Channel Blockers | 1 | 2000 | 167 | 0.040 |
Why?
| | Liver Diseases | 1 | 2022 | 315 | 0.040 |
Why?
| | ROC Curve | 1 | 2020 | 554 | 0.040 |
Why?
| | Heart | 1 | 2002 | 655 | 0.040 |
Why?
| | Albuminuria | 2 | 2014 | 185 | 0.040 |
Why?
| | Renal Elimination | 1 | 2016 | 6 | 0.030 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2000 | 329 | 0.030 |
Why?
| | Natriuresis | 1 | 2016 | 15 | 0.030 |
Why?
| | Gene Expression | 1 | 2000 | 1502 | 0.030 |
Why?
| | Aldosterone | 1 | 2014 | 45 | 0.030 |
Why?
| | Proteins | 1 | 2000 | 1009 | 0.030 |
Why?
| | Prostaglandins | 1 | 2014 | 97 | 0.030 |
Why?
| | Liver Function Tests | 1 | 2014 | 114 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2000 | 1164 | 0.030 |
Why?
| | Forecasting | 1 | 2016 | 389 | 0.030 |
Why?
| | Arachidonate 12-Lipoxygenase | 1 | 2013 | 18 | 0.030 |
Why?
| | Genetic Association Studies | 1 | 2016 | 377 | 0.030 |
Why?
| | Arachidonate 15-Lipoxygenase | 1 | 2013 | 23 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 2 | 2020 | 2691 | 0.030 |
Why?
| | Overweight | 1 | 2017 | 558 | 0.020 |
Why?
| | United States | 1 | 2010 | 14841 | 0.020 |
Why?
| | Pregnancy | 1 | 2025 | 6763 | 0.020 |
Why?
| | Phenotype | 2 | 2016 | 3196 | 0.020 |
Why?
| | Cystic Fibrosis | 1 | 2000 | 1114 | 0.020 |
Why?
| | Cohort Studies | 1 | 2020 | 5742 | 0.020 |
Why?
| | Nitric Oxide | 1 | 2014 | 915 | 0.020 |
Why?
| | Body Mass Index | 1 | 2017 | 2389 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 5131 | 0.020 |
Why?
| | Aged | 3 | 2020 | 23961 | 0.020 |
Why?
| | Child | 1 | 2006 | 21935 | 0.020 |
Why?
| | Inflammation | 1 | 2014 | 2837 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2014 | 5472 | 0.010 |
Why?
| | Signal Transduction | 1 | 2014 | 5079 | 0.010 |
Why?
| | Pedigree | 1 | 2000 | 514 | 0.010 |
Why?
| | Echocardiography | 1 | 2002 | 642 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2000 | 1738 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2007 | 15657 | 0.000 |
Why?
|
|
Brosnahan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|